Meta-analysis of routine blood tests as predictors of mortality in COPD

Article English OPEN
Lomholt, Frederikke K. ; Laulund, Anne S. ; Bjarnason, Nina H. ; Jørgensen, Henrik L. ; Godtfredsen, Nina Skavlan (2014)

Objective: The purpose of this study was to examine whether routine blood tests can be useful in predicting mortality in COPD patients.Methods: Eligible studies were found through a search conducted in the PubMed and Embase databases, the Cochrane Library, and the Web of Knowledge. Twelve studies were included for the meta-analysis of five biochemical markers. Pooled odds ratios (ORs), matching 95% confidence intervals (CIs), and p-values for each of the biochemical markers were calculated using the random effect model.Results: The following four examined biochemical markers were shown to be associated with mortality in patients suffering from COPD: anemia (OR=2.62, 95% CI: 1.60; 4.29, p=0.01), hypoalbuminemia (OR=2.90, 95% CI: 1.56; 5.40, p=0.0008), elevated NT-proBNP (OR=7.54, 95% CI: 4.04; 14.10, p<0.00001), and elevated cardiac troponin T (OR=3.10, 95% CI: 1.11; 8.25, p=0.03). hs-CRP was not found to be associated with increased mortality.Conclusion: In this study, we found that anemia, hypoalbuminemia, elevated NT-proBNP, and elevated cardiac troponin T were associated with increased mortality in patients suffering from COPD.Keywords: COPD; mortality; blood tests; meta-analysis(Published: 5 June 2014)Citation: European Clinical Respiratory Journal 2014, 1: 24110 - http://dx.doi.org/10.3402/ecrj.v1.24110
  • References (38)
    38 references, page 1 of 4

    1. Vestbo J, Hurd SS, Agust´ı AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187: 347 65.

    2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370: 765 73.

    3. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006; 28: 1245 57.

    4. WHO. Chronic obstructive pulmonary disease (COPD) [updated 2013 October]. http://www.who.int/mediacentre/factsheets/ fs315/en/index.html [cited 2013 October 17].

    5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.

    6. Sta˚hl E, Lindberg A, Jansson SA, Ro¨ nmark E, Svensson K, Andersson F. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005; 3: 56.

    7. Rutten-van Mo¨ lken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006; 130: 1117 28.

    8. Barnes N, Calverley PM, Kaplan A, Rabe KF. Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med. 2013; 13: 54.

    9. Vestbo J1, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B. Should we view COPD differently after ECLIPSE? A Clinical Perspective from the Study Team. Am J Respir Crit Care Med. 2014; 189: 1022 30.

    10. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000; 118: 1278 85.

  • Related Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark